MEMBER'S AREA
GET IN TOUCH
JOIN US!

Join us - become a member of ISCBH!

Membership of the ISCBH will give you the opportunity to be part of an international forum for networking and collaborations with leading experts in the field.  You can also benefit from access to educational resources, discounts to attend our meetings and other educational activities, eligibility for grants and awards, updates and news from field. Being part of our community will help you through your career.

ISCBH Membership runs for 2 years in line with ICCBH. To ensure all memberships are in line with this cycle, any members that joined before ICCBH 2024 will be due for renewal in January 2026.

If you join between now and July 2025 you can join at a discounted rate of €150 for a full membership and €75 for the concessionary rate. These members will renew in January 2026

To apply for membership
please fill out the application form using the link below
APPLICATION FORM

Clinicians and
Scientists

€ 150 FOR 2 YEARS
  • Must be a Clinician or Scientist and have interests and/or involvement in the field of paediatric bone. Your institution or affiliation should be included in your application.

Students, Trainees and
Allied Health Professionals

€ 75 FOR 2 YEARS
  • Must be working towards a qualification in, have an interest and involvement in paediatric bone or work as an Allied Health Professional (e.g., physiotherapy, occupational therapy, nursing) in this field. There should be contributions to the field. Head of department or tutors contact details must be provided during the application.

Concessionary
membership

€ 75 FOR 2 YEARS
  • Available to those from low and middle income countries as described by the world bank.

Membership is biennial in line with our conference. If you join up to and including June 2024 your membership will renew in January 2026. Full membership for qualified clinicians and scientist is €200 and €100 concessionary rate. If you join July 2024 to July 2025 you can join at a discounted rate of €150 for full membership and €75 for the concessionary rate – this will also renew in January 2026. 

ISCBH HOME

Registered Office: Kaiser Josef Straße 9, 6020 Innsbruck, Austria

© 2023 International Society for Children’s Bone Health

Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our Rare Disease division is focused on generating scientific and technological breakthroughs for people living with a rare disease via the discovery and development of integrated therapeutic solutions and novel indications of established medicines in rare and ultra-rare blood, endocrine and renal disorders. Novo Nordisk employs about 50,800 people in 80 countries out of which 3.300 within rare disease.

WEBSITE

Kyowa Kirin strives to create and deliver novel medicines with life-changing value. As a Japan-based Global Specialty Pharmaceutical Company with a heritage of 70+ years, we apply cutting-edge science including an expertise in antibody research and engineering, to address the needs of patients and society across multiple therapeutic areas including Nephrology, Oncology, Immunology/Allergy and Neurology. Across four regions – Japan, Asia Pacific, North America and EMEA/International – we focus on our purpose, to make people smile, and are united by our shared values of commitment to life, teamwork/Wa*, innovation and integrity.

*Harmony and loop among people.

WEBSITE

Founded in 2007, Ascendis Pharma is applying its innovative TransCon™ technology platform to build a leading, fully integrated biopharma company focused on making a meaningful difference in patients’ lives. Guided by our core values of patients, science and passion, we use our TransCon technologies to fulfill our mission of developing new and potentially best-in-class therapies that address unmet medical needs. Ascendis is headquartered in Copenhagen, Denmark, and has additional facilities in Europe and the United States.

WEBSITE

Inozyme Pharma is a rare disease biopharmaceutical company developing novel therapeutics for the treatment of diseases driven by pathologic mineralization and intimal proliferation which impact the vasculature, soft tissue and skeleton. We are initially focused on developing an enzyme therapy to treat ENPP1 and ABCC6 Deficiencies, rare genetic diseases associated with significant morbidity, mortality, and unmet medical need.

WEBSITE

BioMarin is a world leader in developing and commercializing innovative therapies for rare diseases driven by genetic causes. With a 20-year history, BioMarin remains steadfast to its original mission—to bring new treatments to market that will make a big impact on small patient populations. These conditions are often inherited, difficult to diagnose, progressively debilitating, have few, if any, treatment options, and are usually ignored. Visit www.biomarin.com to learn more.

WEBSITE

Alexion, AstraZeneca Rare Disease, is the group within AstraZeneca focused on rare diseases, created following the 2021 acquisition of Alexion Pharmaceuticals, Inc. As a leader in rare diseases for 30 years, Alexion is focused on serving patients and families affected by rare diseases and devastating conditions through the discovery, development and commercialization of life-changing medicines. Alexion focuses its research efforts on novel molecules and targets in the complement cascade and its development efforts on hematology, nephrology, neurology, metabolic disorders, cardiology and ophthalmology. Headquartered in Boston, Massachusetts, Alexion has offices around the globe and serves patients in more than 50 countries.

WEBSITE